Looks like you’re on the UK site. Choose another location to see content specific to your location
Sanofi Launches High-Dose Flu Vaccine for UK Seniors
Sanofi has unveiled its high-dose quadrivalent influenza vaccine (QIV-HD) in the UK, aiming to limit flu protection for individuals aged 65 and over, as well as at-risk groups aged 60-64. Endorsed by the JCVI and reimbursable via the NHS, this vaccine represents a significant advancement in flu prevention, now available for the 2025/26 flu season pre-orders.
The introduction of QIV-HD marks a development in flu vaccination strategies, emphasizing improved efficacy for older adults who often face severe complications from the flu.
The high-dose vaccine’s enhanced performance over standard-dose alternatives is backed by over a decade of data, including randomized trials. A meta-analysis further supports its effectiveness, showing notable reductions in pneumonia and cardiorespiratory hospitalizations. Sanofi’s global vaccine distribution, exceeding 250 million doses annually, highlights its commitment to public health.
Sanofi’s introduction of the QIV-HD vaccine is a testament to its dedication to addressing vulnerabilities in older populations, especially against the backdrop of evolving flu strains. By leveraging high-quality data and clinical evidence, this initiative promises to make a substantial impact on safeguarding senior health, setting a new standard for influenza prevention in the UK.
For the latest updates and in-depth insights into the world of Consumer Healthcare, including breakthrough treatments, industry trends, and regulatory news, contact Marcus Chalk today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard